BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38147624)

  • 1. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
    Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
    Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.
    Stoddart A; Fernald AA; Wang J; Davis EM; Karrison T; Anastasi J; Le Beau MM
    Blood; 2014 Feb; 123(7):1069-78. PubMed ID: 24381225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
    Schneider RK; Ademà V; Heckl D; Järås M; Mallo M; Lord AM; Chu LP; McConkey ME; Kramann R; Mullally A; Bejar R; Solé F; Ebert BL
    Cancer Cell; 2014 Oct; 26(4):509-20. PubMed ID: 25242043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion.
    Stalmann USA; Ticconi F; Snoeren IAM; Li R; Gleitz HFE; Cowley GS; McConkey ME; Wong AB; Schmitz S; Fuchs SNR; Sood S; Leimkühler NB; Martinez-Høyer S; Banjanin B; Root D; Brümmendorf TH; Pearce JE; Schuppert A; Bindels EMJ; Essers MA; Heckl D; Stiehl T; Costa IG; Ebert BL; Schneider RK
    Blood Adv; 2022 Mar; 6(6):1780-1796. PubMed ID: 35016204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
    Bello E; Pellagatti A; Shaw J; Mecucci C; Kušec R; Killick S; Giagounidis A; Raynaud S; Calasanz MJ; Fenaux P; Boultwood J
    Br J Haematol; 2015 Oct; 171(2):210-214. PubMed ID: 26085061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
    Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
    Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
    Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
    Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Göhring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellström-Lindberg E
    Haematologica; 2014 Jun; 99(6):1041-9. PubMed ID: 24682512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
    Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
    EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.
    Stoddart A; Wang J; Fernald AA; Karrison T; Anastasi J; Le Beau MM
    Blood; 2014 Jan; 123(2):228-38. PubMed ID: 24264229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
    Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
    Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-derived CK1α mutations enhance MDMX inhibition of p53.
    Liu X; Huang Q; Chen L; Zhang H; Schonbrunn E; Chen J
    Oncogene; 2020 Jan; 39(1):176-186. PubMed ID: 31462704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
    Lee JH; List A; Sallman DA
    Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
    Hosono N
    Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis.
    Kamio T; Gu BW; Olson TS; Zhang Y; Mason PJ; Bessler M
    PLoS One; 2016; 11(4):e0152263. PubMed ID: 27042854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
    Liu T; Krysiak K; Shirai CL; Kim S; Shao J; Ndonwi M; Walter MJ
    PLoS One; 2017; 12(2):e0170470. PubMed ID: 28178280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.